CG Oncology (CGON) Income from Continuing Operations (2023 - 2026)
CG Oncology (CGON) reported Income from Continuing Operations of 60101000.0 for Q1 2026, down 74.42% on a YoY basis from 234982430.16 in Q1 2025, and down 45.68% quarter-over-quarter from 41256000.0 in Q4 2025.
CG Oncology (CGON) Income from Continuing Operations (2023 - 2026) Analysis & Trends
CG Oncology has reported Income from Continuing Operations for 4 years, with the latest figure at 60101000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 74.42% year-over-year to 60101000.0; the trailing twelve-month figure through Mar 2026 stood at 186487000.0 (down 76.64% YoY), and the FY2025 full-year result was 160843000.0, down 82.69% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 60101000.0, down from 41256000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 8675000.0 in Q1 2023, with the low at 60101000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 27502076.92 across 4 years, with a median of 20403000.0 in 2024.
- The largest YoY upside for Income from Continuing Operations was 29.72% in 2025 against a maximum downside of 119.05% in 2025.
- CG Oncology's Income from Continuing Operations stood at 16551000.0 in 2023, then slumped by 92.16% to 31804000.0 in 2024, then slipped by 29.72% to 41256000.0 in 2025, then slumped by 45.68% to 60101000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 60101000.0 (Q1 2026), 41256000.0 (Q4 2025), and 43708000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | -60.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.10 Mn |
| Dec 31, 2025 | -41.26 Mn |
| Sep 30, 2025 | -43.71 Mn |
| Jun 30, 2025 | -41.42 Mn |
| Mar 31, 2025 | -34.46 Mn |
| Dec 31, 2024 | -31.80 Mn |
| Sep 30, 2024 | -20.40 Mn |
| Jun 30, 2024 | -18.91 Mn |
| Mar 31, 2024 | -16.93 Mn |
| Dec 31, 2023 | -16.55 Mn |
| Sep 30, 2023 | -11.76 Mn |
| Jun 30, 2023 | -11.56 Mn |
| Mar 31, 2023 | -8.68 Mn |